Press Esc to close

Welcome to Money Morning - Only the News You Can Profit From.

Close

Cash in on Apple's Smash-Hit iPhone 6 – Without Buying a Single Share

Shares of Apple Inc. (Nasdaq: AAPL) cracked the $100-a-share threshold this week and set a new all-time record of $101.09 as investors have suddenly realized the iDevice king is gearing up for a monster grand finale to 2014.

You’re not surprised, of course. Apple shares have gained nearly 70% since Capital Wave Forecast Editor Shah Gilani recommended the stock to you on July 10, 2013. And they’ve zoomed nearly 26% since Shah re-recommended the shares at the very end of last year… Full Story

  • Featured Story

    Stocks to Buy: Intercept Pharma (Nasdaq: ICPT) Ready to Double

    20140611-stocks-to-buy

    Usually the best stocks to buy have not already tripled in value within the past six months.

    But then there's Intercept Pharmaceuticals Inc. (Nasdaq: ICPT).

    This biotech stock soared more than 500% in two days on the news its innovative and promising hepatitis drug obeticholic acid, or OCA, had a trial stopped early because the drug met the goals of the study.

    Bulls have refused to be distracted by some negative news that has pushed the stock back under $300 in the meantime.


    The crazy thing is, Intercept Pharma could actually double from here...
  • biotech stocks to buy

  • The Secret to Making Money from Bioscience's "Scariest Event"

    In bioscience investing, binary catalysts are milestone events that signal a thumbs-up or thumbs- down for an experimental drug as it makes its way through the regulatory process.

    Positive catalysts can send a share price soaring. Negative ones can send it into a nosedive.

    Perhaps the least  understood of these catalysts are FDA Advisory Committee (a.k.a. AdCom) recommendations.

    But they're also among the most powerful.

    Here's what I mean, and how to play them profitably... Full Story

    Read More...
  • The Four Telltale Signs of a Bioscience "Blockbuster" in the Making

    The FDA's Expedited Programs help get promising new therapies for seriously ill patients approved as soon as possible.

    But they also create an unintended side effect that's a huge advantage for investors: They point exactly to the biggest money-making opportunities in the bioscience industry.

    They're like big, green, neon signs that say, "This is an important drug with incredible profit potential."

    And this is how you find them... Full Story

    Read More...
  • Best Stocks to Buy Now: A Hot Biopharma, an Energy Sector Worth $2 Trillion, and More stocks to buy

    Our roundup of the best stocks to buy last week gave Money Morning Members more than a dozen plays in 2014's most profitable sectors.

    One pick involves a possible healthcare merger that would combine two industry titans. The duo would create an industry powerhouse with a market cap near $300 billion. Another play revolves around one of the most highly anticipated, and possibly biggest, initial public offerings ever. And a special report from our small-cap trading specialist showed readers a technique for uncovering investment winners today.

    Here they are – with more opportunities – in our latest Money Morning best stocks to buy list:
  • Stocks to Buy: Why This Biopharma Company Is a “Long-Term Profit Machine” 20140509-stocks-to-buy-CARA

    One strategy experts use when looking for the best biotech stocks to buy is finding companies with promising drug candidates that are close to receiving regulatory approval. When these drugs hit the market, they can bring in billions in revenue.

    When companies have multiple promising drugs in their product pipeline, they become even more attractive because they have more than one shot at finding a revenue blockbuster.

    That’s why Money Morning’s Defense & Tech Specialist Michael A. Robinson likes this biotech stock to buy now…
  • Stocks to Buy: This Botox Competitor Is Heading Toward Huge Profits 20140429_stocks-to-buy

    When Valeant Pharmaceuticals International Inc. (NYSE: VRX) and activist investor Bill Ackman made an unsolicited $46 billion bid to purchase Botox maker Allergan Inc. (NYSE: AGN) last week, investors got a glimpse of just how big the Botox market is globally.

    And that had us pointing to our "Stocks to Buy" list...

    Money Morning's Defense & Tech Specialist Michael A. Robinson has been recommending a biotech stock that develops similar specialty products for dermatological applications. And it could see huge gains soon...
  • Stocks to Buy: 95% Return Is Just the Start For This Biotech Play Lab worker

    Investors looking for stocks to buy in 2014 have had an abundance of new options as 94 companies have gone public this year, according to Renaissance Capital.

    The average return for those 94 companies since their IPO date is 9%. But some stocks have far outpaced the average, and are still at great buy-in points even after huge gains.

    Money Morning's Defense and Tech Specialist Michael Robinson has found a stock that still provides investors a great profit opportunity, even after posting a 95% return from its IPO date...
  • Three Orphan Drug Stocks to Buy When the Biotech Market Is Down best biotech investments 2014

    There's no sugarcoating it: Biotech stocks have had a rough run in the past month.

    But when other investors are running for the hills, Money Morning experts are finding profit plays. With biotech stocks trading lower, there are excellent buy-in opportunities on valuable biotech companies.

    Orphan drugs offer some of the best profit plays in biotech as the have extremely lucrative markets cornered.

    And these three stocks to buy are the best orphan drug plays now...
  • There Is No Biotech Bubble; Here's the Real Story 20140331_IPO-bubble

    Some analysts feel that the biotech sector's recent tumble is evidence of the biotech bubble bursting.

    But they're wrong; the market is simply in a period of adjustment.

    The premise behind the bubble idea is that biotech companies as a group are overvalued, that their market caps aren't supported by performance. In other words, that their perceived value is all smoke and mirrors.

    The problem with that argument is, these analysts are using a mass of technical indicators to support it. Anyone who's followed start-up biotechs knows that's a fool's errand.
  • Finding the Blockbuster That Will Make You Rich In the pharmaceutical industry, a "blockbuster" is any drug that brings in $1 billion or more in revenue per year. It's the prize that every biotech hopes to win - and every biotech investor hopes to cash in on. So how do you spot one in the making? If the market suspects a drug candidate has blockbuster potential, catalysts (events like positive clinical study results and regulatory milestones) will give its manufacturer's share price a big, big boost. There is no crystal ball that's 100% accurate when experimental drugs are concerned, but here are some telling questions that can narrow your search... Full story...
  • The Secret Behind This Controversial Industry's Leader

    As a long-time tech-investing analyst, I have one of the best vantage points in the country for tracking profitable marijuana industry trends.

    Here's the thing: I live 10 minutes from the epicenter of the medical marijuana movement in northern California, and the rest of the nation for that matter.

    Downtown Oakland contains a small cannabis-friendly district known as "Oaksterdam." In fact, there's a patient co-op across the street from a store where I buy my fedoras.

    I bring all this up so you know I've followed what's been happening with the marijuana legalization movement for years.

    In these parts, it's difficult to avoid - you see lots of folks walking around wearing their official Oaksterdam t-shirts.

    Since California legalized medical marijuana in 1996, another 19 states have joined the movement.

    The San Francisco-based market research firm ArcView Group estimates the national legal marijuana market at $1.53 billion in 2013. ArcView expects sales to nearly double to $2.57 billion by the end of this year.

    Read More...
  • Double Your Money with Our "High-Tech GPS"

    Early last year, I saw a research study that said nearly 60% of all U.S. workers have a net worth of less than $25,000.

    And that means they have no retirement.

    From the moment that I saw that research, I knew I had a mission - to help folks reclaim their financial futures by breaking free of Wall Street's self-serving shackles... and creating wealth all on their own.

    And I knew there was one avenue to travel - the high-tech highway.

    So I developed a roadmap - a set of five rules - that would serve as a kind of "tech-investing GPS." My goal was to help investors identify "double-your-money" tech stocks - and navigate their way to massive high-tech wealth.

    Today I'm going to walk you through those rules again, and also give you a bonus - a biotech stock with double-your-money potential.

    So let's get started...
  • Three Bioscience Breakthroughs You Can't Afford to Miss You can make huge gains investing in a breakthrough drug, but you can do even better putting your money into a new, cutting-edge technology platform that can fuel a company's entire pipeline. One biotech I recommended to my BioScience Millionaire subscribers last July, Sangamo Biosciences Inc. (Nasdaq: SGMO), has developed a technology from naturally occurring molecules, called zinc finger proteins (ZFPs), that scientists can engineer to edit specific genes in the human genome. It can cut them out, replace them, or add new ones - in other words, it plays with the basic building blocks of life as if they were Lego pieces! Sangamo is currently using ZFP technology to find cures for some of the most intractable - and often un-druggable - diseases we know of, including HIV, Alzheimer's, Huntington's, and Down's syndrome to name a few. And Sangamo isn't the only company using ZFPs for research. In fact, it licenses out the technology to scientific institutions and companies all over the world - providing it with a great revenue stream. As a result, SGMO shares have gone up more than 150% since last summer. Actually, if you'd had the foresight to buy the stock at the beginning of 2012, you'd now be realizing profits of 577% on your money. The magic word in that sentence is "foresight." The trick is to spot these technologies early in their development, either before they've had IPOs or soon after. With that in mind, here are a few exciting new technologies to keep an eye on... Full Story Read More...
  • Penny Stocks to Watch Top 10 Penny Stocks this year

    The recent spate of uninspiring data, from unemployment to retail sales, has been blamed on the unrelenting cold and snowy winter. But one group that hasn't been affected, and isn't using the convenient "bad weather" excuse, is this list of penny stocks to watch now.

    This week brought huge gains from several low-priced stocks across all sectors:

    Here are four penny stocks to watch now.
  • This Patent Cliff 2014 Chart Shows How Much Revenue Big Pharma Will Lose diver

    More pharmaceutical companies will lose drug patents to the patent cliff in 2014, threatening billions of dollars in revenue for Big Pharma.

    Once a drug is off patent, other pharmaceutical companies are free to replicate the product. That can drastically slash the revenue of pharmaceutical companies that have been making billions of dollars from their patented products.

    Just look at this patent cliff chart illustrating how much the biggest pharmaceutical companies stand to lose:
  • Penny Stocks: Today's Biggest Movers Today's Penny Stock Earnings

    A number of penny stocks showed investors some love today (Friday) with huge share-price climbs.

    While the Dow Jones Industrial Average rose just under 1% by 2 p.m., these hot penny stocks were up double digits.

    Following are five of Friday's biggest low-priced movers.